Gates Foundation welcomes HR 5501

10 March 2008

Tachi Yamada, president of the Bill & Melinda Gates Foundation's Global Health Program, has applauded the passage of the Tom Lantos and Henry J Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act (HR 5501) by the House Committee on Foreign Affairs.

He said that "this bipartisan bill is an important step toward renewing and strengthening the US commitment to fighting AIDS, TB, and malaria - diseases that, together, kill nearly five million people every year."

Dr Yamada continued: "the bill would increase US support for the President's Emergency Plan for AIDS Relief (PEPFAR), the President's Malaria Initiative and the Global Fund to Fight AIDS, TB and Malaria. Each of these initiatives has proven to be a wise investment of US resources, and has achieved tremendous success in a short period of time. When PEPFAR was launched, it was a bold move - and some were skeptical that it would work. But the evidence is in, and global AIDS spending has been a powerful force for saving lives."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight